Follow us on Twitter
This page is updated frequently with new Immune Disease-related patent applications. Subscribe to the Immune Disease RSS feed to automatically get the update: related Immune RSS feeds. RSS updates for this page: Immune Disease RSS
|| List of recent Immune Disease-related patents
|Nitrogen mustard derivatives|
The disclosure includes compounds of formula (1): wherein x1, x2, q, z, r1, and r2 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds..
|Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders|
Wherein r1a, r1b, r2, r4, r5, r6a, r6b, r7, r8, w, x, cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention..
|Novel pd1 isoforms, and uses thereof for potentiating immune responses|
In one embodiment, the present invention provides a new isoform of human pd1 (Δ42pd1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. Δ42pd1 does not engage pd-l1/pd-l2, and can induce the production of pro-inflammatory cytokines in one embodiment, Δ42pd1 can be used as an intramolecular adjuvant to develop a fusion dna vaccine for enhancing antigen-specific cd8+ t cell immunity and for prevention of pathogenic infection and/or cancer.
|Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases|
The present invention provides human anti-il-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to il-6 and that has an extended in vivo half-life for the treatment and prevention of il-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors..
|Methods for the treatment and prevention of inflammatory diseases|
The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from helicobacter pylori activates nkt cells in a cd1d-restricted fashion, and is protective against ahr in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by nkt cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative nkt cells and foxp3+ treg cells.
|Metap-2 inhibitor polymersomes for therapeutic administration|
The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising metap-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety..
|Method to screen for selective peptides that inhibit the biological activity of calcineurin|
The invention relates to the biotechnology sector involving the area of human health. More specifically, the invention is based on the surprising usefulness of peptides lxvpc1, c3 and c4 as efficient selective inhibitors of the calcineurin signalling pathway (cn)-nfat and the phosphate activity of cn.
|Peptide secreted by lactobacillus plantarum with immunomodulating function|
To summarize, the st peptide is considered to promote the process of immunologic ignorance of our gastrointestinal immune system toward the commensal bacteria of our gastrointestinal tract, thus favoring the mechanisms of oral tolerance. Therefore the st peptide could be used in immunotherapy, especially in the context of certain autoimmune diseases and certain inflammatory diseases..
|Pharmaceutically active disubstituted pyridine derivatives|
The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase..
|1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities|
Which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-fms (csf-1r), c-kit, and/or pdgfr kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-fms, c-kit, or pdgfr kinases..
The present invention provides compounds, compositions and methods for treatment and/or prevention of neurodegenerative diseases, including but not limited to autoimmune diseases, such as multiple sclerosis, in which demyelination, (the loss of the myelin sheath that insulates the nerves) is an associated or causative feature. The data provided demonstrate the utility of the compounds and compositions according to this invention to promote oligodendrogenesis and myelination or remyelination..
|Genes differentially expressed by cumulus cells and assays using same to identify pregnancy competent oocytes|
A genetic means of identifying “pregnancy competent” oocytes is provided. The means comprises detecting the level of expression of one or more genes that are expressed at characteristic levels (upregulated or downregulated) in cumulus cells derived from pregnancy competent oocytes.
|Nanoparticle compositions for generation of regulatory t cells and treatment of autoimmune diseases and other chronic inflammatory conditions|
The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (lsec) and/or kupffer cells, and for the in vivo generation of regulatory t cells, notably cd4+cd25+foxp3+ regulatory t cells (treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory t cells.
|Combination treatment comprising a hdac6 inhibitor and an akt inhibitor|
The invention provides compositions comprising a histone deacetylase 6 (hdac6) inhibitor and an akt inhibitor, pharmaceutical compositions/formulations and kits of parts comprising the same; optionally further comprising one or more anti-cancer agents. The compositions of the invention provide for surprisingly efficacious killing of inter alia, cancer cells.
|T-reg cell expansion|
This invention relates to methods of expanding t regulatory cells through ox40l and jagged-1 induced signaling. The methods can be used for treating autoimmune diseases..
|Treatment of autoimmune diseases|
Compositions can be used to stimulate growth of a hair shaft from a hair follicle. These compositions can include methylated polynucleotides useful in treatment of autoimmune diseases or conditions, including those, such as alopecia areata, that result in hair loss..
|Selective inhibition of malt1 protease by phenothiazine derivatives|
Wherein x is n or c; y is s, o, so2, so, nh, co, ch2, ch═ch, ch2═ch2; ( )z is a c1-c5 linear or branched alkyl chain; a is nr3r4, or or5, or het; r1 and r2 in each occurrence are independently selected from —h, —ch3, —oh, —och3, —sch3, —f, —cl, —cf3, —nh2, and —cooh; r3, r4, and r5 are h, or c1-c5 linear or branched alkyl groups, and het is a heterocyclic ring of 5, 6, or 7 members, wherein the ring atoms can be c, o, n, or s, the ring can be saturated or aromatic, and the ring can be substituted with h or c1-c5 linear or branched alkyl groups; or a pharmaceutically acceptable salt, prodrug, enantiomer, diastereomer, racemic mixture, crystalline form, amorphous form, unsolvated form or solvate of said compound. The compound of the invention may further be used in the treatment of malt1-dependent immune diseases..
|Therapeutic compositions and methods|
Pad4 inhibitory compositions and methods for their use in treatment of cancer and autoimmune disease are provided according to embodiments of the present invention.. .
This invention is directed in part to methods, assays and/or kits for identifying an individual who has an autoimmune disease (such as rheumatoid arthritis), or who has an altered risk for having or developing the autoimmune disease. The methods in one aspect comprise determining the presence or absence of a nucleic acid variant within the somatostatin receptor type 2 (sstr2) gene in the individual's nucleic acids, wherein the presence of the nucleic acid variant is correlated with having the autoimmune disease or the altered risk.
Popular terms: [SEARCH]
Immune Disease topics: Immune Disease, Autoimmune, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Immune Disorder, Transplant, Autoimmune Disorders, Type 1 Diabetes, Autoimmune Disorder, Proliferative Disorder, Signs And Symptoms, Proliferative, Antagonist, Recurrence
Follow us on Twitter
This listing is a sample listing of patent applications related to Immune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.